A PON1 genetikai variánsai és hatásuk a metabolikus egészségre

Metabolic disorders, including dyslipidemia, diabetes, and liver diseases, are often exacerbated by chronic inflammation and oxidative stress. Paraoxonase 1 (PON1) is an enzyme produced in the liver that plays a crucial role in protecting the body from oxidative damage by hydrolyzing oxidized lipids. Genetic variations in the PON1 gene can influence the enzyme's expression and activity, thereby affecting an individual's susceptibility to various metabolic and cardiovascular diseases. This study aimed to investigate the genetic determinants of serum paraoxonase (PONase) activity and their relationship with dysmetabolic phenotypes, particularly in older adults. In a genome-wide association study involving 922 Portuguese participants from the PREVADIAB2 cohort, researchers identified two significant PON1 variants: rs2057681 and rs854572. The rs2057681 variant is linked to the non-synonymous Q192R variant, while rs854572 is located in the promoter region of the gene. The analysis of haplotypes formed by these variants revealed that certain combinations can either increase or decrease the risk of dysglycemia and liver fibrosis, depending on the genotype context of rs2057681. Notably, while PONase activity was strongly associated with these PON1 variants, it did not directly correlate with dysmetabolic phenotypes, indicating that the genetic context and haplotype structure are crucial in determining disease susceptibility. These findings have practical implications for individuals concerned about their metabolic health. Understanding one’s PON1 genotype could help identify those at higher risk for conditions like diabetes and liver disease. For instance, individuals with specific haplotypes may benefit from targeted lifestyle interventions, such as dietary modifications or increased physical activity, to mitigate their risk. Additionally, healthcare providers could consider genetic testing for PON1 variants as part of a comprehensive metabolic health assessment. The findings are particularly relevant to biomarkers associated with metabolic health, such as fasting glucose, ALT, and GGT. Individuals with dysglycemia or elevated liver enzymes may want to explore their PON1 genetic variants to better understand their metabolic risk profile. Metabolicum's calculators, such as those evaluating fasting glucose and liver health markers, can provide valuable insights based on these genetic factors. In conclusion, the study underscores the complex interplay between genetics and metabolic health. By recognizing the role of PON1 genetic variants, individuals can take proactive steps in managing their metabolic health. Genetic insights can help tailor prevention strategies for metabolic liver disease and diabetes, emphasizing the importance of personalized health approaches.